老年非瓣膜性房颤患者起始口服抗凝药的医疗资源利用和费用数据集
基于Medicare数据库分析老年非瓣膜性房颤患者起始不同口服抗凝药的医疗资源利用和费用差异。
基本信息
资源简介
老年非瓣膜性房颤患者起始口服抗凝药的医疗资源利用和费用数据集
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 1 个文件、合计 74.57 KB，主题涵盖 Healthcare costs、novel oral anticoagulants、older-aged patients、non-valvular atrial fibrillation、economic burden，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants》。配套论文《Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants》发表于 Journal of Medical Economics（2019），DOI：10.1080/13696998.2019.1672698。源站首次发布：2019-10-12。
【数据内容】
源站原始描述：Aims: Non-valvular atrial fibrillation (NVAF) prevalence increases with age. Hence, evaluating the economic burden among older-aged patients is vital. This study aimed to compare healthcare resource utilization (HRU) and costs among newly-diagnosed older-aged NVAF patients treated with warfarin, rivaroxaban, or apixaban vs. dabigatran. Materials and Methods: Newly-diagnosed older-aged (aged ≥65 years) NVAF patients initiating dabigatran, warfarin, rivaroxaban, or apixaban (first prescription dat…
中文译文（机器翻译，仅供快速理解，请以原文为准）：目的：非瓣膜性心房颤动（NVAF）的患病率随年龄增长而增加。因此，评估老年患者的经济负担至关重要。本研究旨在比较新诊断的老年NVAF患者中，接受华法林、利伐沙班或阿哌沙班治疗者与接受达比加群治疗者的医疗资源利用（HRU）和成本。 材料与方法：从100% Medicare数据库中纳入2010年1月1日至2015年12月31日期间新诊断的老年（年龄≥65岁）NVAF患者，这些患者开始使用达比加群、华法林、利伐沙班或阿哌沙班（首次处方日期=索引日期），且在索引日期前连续入组≥12个月。患者数据评估至停药/换药/剂量变更/死亡/退保/研究结束（最长12个月）。达比加群起始者分别与华法林、利伐沙班或阿哌沙班起始者进行1:1倾向评分匹配（PSM）。采用广义线性模型比较匹配队列之间的全因HRU和每患者每月（PPPM）成本。 结果：与达比加群进行PSM后，分别识别出70,531例华法林、51,673例利伐沙班和25,209例阿哌沙班患者。达比加群患者的广义线性模型校正后PPPM住院次数（0.114 vs. 0.123；0.111 vs. 0.121）和门诊就诊次数（2.864 vs. 4.201；2.839 vs. 2.949）分别显著少于华法林和利伐沙班患者，但PPPM住院次数（0.103 vs. 0.090）和门诊就诊次数（2.780 vs. 2.673）显著多于阿哌沙班患者（所有p p p）。 局限性：本研究受任何索赔数据集固有局限性的影响，包括编码错误可能导致的偏倚，以及使用诊断代码而非临床证据来识别医疗状况。通过非处方途径购买或由医生提供的药物样本永远不会被索赔数据捕获。 结论：新诊断的老年NVAF患者中，开始使用达比加群者的校正后全因HRU和成本显著低于华法林和利伐沙班患者，但校正后HRU和成本高于阿哌沙班患者。
【数据结构与技术规格】
文件数 1 个，合计 74.57 KB。ijme_a_1672698_sm8137.xlsx：application/vnd.openxmlformats-officedocument.spreadsheetml.sheet，74.57 KB。数据集 DOI：10.6084/m9.figshare.9897323.v2。
【主题与分类】
源站学科分类：Medicine、Biological Sciences not elsewhere classified、Cancer、Science Policy、Hematology。主题标签：Healthcare costs、novel oral anticoagulants、older-aged patients、non-valvular atrial fibrillation、economic burden。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_and_expenditures_among_newly-diagnosed_elderly_non-valvular_atrial_fibrillation_patients_initiating_oral_anticoagulants/9897323
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. Taylor & Francis. Chowdhury, Ritam; Franchino-Elder, Jessica; Wang, Li; Yuce, Huseyin; Wang, Cheng; Hartaigh, Briain O
【使用注意】
· 源站最后修改于 2024-02-28，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants
- DOI：10.6084/m9.figshare.9897323.v2
- 发布日期：2019-10-12
- 文件数：1 个
- 文件总体积：74.57 KB
- 源站页面：https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_and_expenditures_among_newly-diagnosed_elderly_non-valvular_atrial_fibrillation_patients_initiating_oral_anticoagulants/9897323
命令行下载
curl -L -o "ijme_a_1672698_sm8137.xlsx" "https://ndownloader.figshare.com/files/17786513"
文件清单
ijme_a_1672698_sm8137.xlsx（74.57 KB）
文件总体积 74.57 KB（源站 API 实测）。
数据说明
Aims: Non-valvular atrial fibrillation (NVAF) prevalence increases with age. Hence, evaluating the economic burden among older-aged patients is vital. This study aimed to compare healthcare resource utilization (HRU) and costs among newly-diagnosed older-aged NVAF patients treated with warfarin, rivaroxaban, or apixaban vs. dabigatran.
Materials and Methods: Newly-diagnosed older-aged (aged ≥65 years) NVAF patients initiating dabigatran, warfarin, rivaroxaban, or apixaban (first prescription date = index date) from 01JAN2010-31DEC2015 and with continuous enrollment for ≥12 months pre-index date were included from 100% Medicare database. Patient data were assessed until drug discontinuation/switch/dose change/death/disenrollment/study end (up to 12 months). Dabigatran initiators were 1:1 propensity score-matched (PSM) with warfarin, rivaroxaban, or apixaban initiators. Generalized linear models were used to compare all-cause HRU and costs per-patient-per-month (PPPM) between the matched cohorts.
Results: After PSM with dabigatran, 70,531 warfarin, 51,673 rivaroxaban, and 25,209 apixaban patients were identified. Dabigatran patients had significantly fewer generalized-linear-model-adjusted PPPM hospitalizations (0.114 vs. 0.123; 0.111 vs. 0.121), and outpatient visits (2.864 vs. 4.201; 2.839 vs. 2.949) than warfarin and rivaroxaban patients, respectively, but had significantly more PPPM hospitalizations (0.103 vs. 0.090) and outpatient visits (2.780 vs. 2.673) than apixaban patients (all p p p Limitations: This study is subject to the inherent limitations of any claims dataset, including potential bias from coding errors and identification of medical conditions using diagnosis codes as opposed to clinical evidence. Medications filled over-the-counter or provided as samples by the physician are never captured in claims data.
Conclusions: Newly-diagnosed older-aged NVAF patients initiating dabigatran incurred significantly lower adjusted all-cause HRU and costs than warfarin and rivaroxaban patients but higher adjusted HRU and costs than apixaban patients.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.9897323.v2（source: https://tandf.figshare.com/articles/dataset/Healthcare_resource_utilization_and_expenditures_among_newly-diagnosed_elderly_non-valvular_atrial_fibrillation_patients_initiating_oral_anticoagulants/9897323）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
